Low-grade systemic inflammation and the development of metabolic diseases: From the molecular evidence to the clinical practice

Cirugia y Cirujanos (English Edition)

Volumn 83, Issue 6, 2015, Pages 543-551

  León Pedroza, José Israel ^a   González Tapia, Luis Alonso ^a   del Olmo Gil, Esteban ^a   Castellanos Rodríguez, Diana ^a   Escobedo, Galileo ^b   González Chávez, Antonio ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Adipose tissue; Arteriosclerosis; Insulin resistance; Low grade systemic inflammation; Macrophages; Metabolic diseases; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; GLUCOSE TRANSPORTER; GLYCOSYLATED HEMOGLOBIN; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; VON WILLEBRAND FACTOR; ADIPOCYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOPHAGY (CELLULAR); CLINICAL PRACTICE; CYTOTOXIC T LYMPHOCYTE; DYSLIPIDEMIA; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN RESISTANCE; LIPID PEROXIDATION; MACROPHAGE; METABOLIC DISORDER; NECROSIS; NF KB SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLARIZATION; TISSUE REPAIR; ARTERIOSCLEROSIS; BIOLOGICAL MODEL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; INTRAABDOMINAL FAT; METABOLIC SYNDROME X; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS);

ADIPOKINES; ARTERIOSCLEROSIS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INTRA-ABDOMINAL FAT; LEPTIN; MACROPHAGES; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NF-KAPPA B; OBESITY; RECEPTORS, PATTERN RECOGNITION; TOLL-LIKE RECEPTORS;

EID: 84946200370     PISSN: 00097411     EISSN: 2444054X     Source Type: Journal    
DOI: 10.1016/J.CIRCEN.2015.11.008     Document Type: Article

References (45)

1. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
2. Van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013;71(4):174-87.
3. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-808.
4. Feng D, Tang Y, Kwon H, Zong H, Hawkins M, Kitsis RN, et al. High-fat diet-induced adipocyte cell death occurs through a cyclophilin D intrinsic signaling pathway independent of adipose tissue inflammation. Diabetes. 2011;60(8):2134-43.
5. Kitamura H, Kimura S, Shimamoto Y, Okabe J, Ito M, Miyamoto T, et al. Ubiquitin-specific protease 2-69 in macrophages potentially modulates metainflammation. FASEB J. 2013;27(12):4940-53.
6. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008;49(7):1562-8.
7. Yoshizaki T, Kusunoki C, Kondo M, Yasuda M, Kume S, Morino K, et al. Autophagy regulates inflammation in adipocytes. Biochem Biophys Res Commun. 2012;417(1):352-7.
8. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia. 2012;55(10):2583-92.
9. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells cytokines, and chemokines. ISRN Inflamm. 2013;22:139239.
10. Suárez-Álvarez K, Solís-Lozano L, Leon-Cabrera S, González-Chávez A, Gómez-Hernández G, Quiñones-Álvarez MS, et al. Serum IL-12 is increased in Mexican obese subjects and associated with low-grade inflammation and obesity-related parameters. Mediators Inflamm. 2013;2013:967067.
11. Sander LE, Davis MJ, Boekschoten MV, Amsen D, Dascher CC, Ryffel B, et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature. 2011;474(7351):385-9.
12. Leulier F, Lemaitre B. Toll-like receptors - taking an evolutionary approach. Nat Rev Genetics. 2008;9(3):165-78.
13. Jialal I, Huet BA, Kaur H, Chien A, Devaraj S. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care. 2012;35(4):900-4.
14. Kopp A, Gross P, Falk W, Bala M, Weigert J, Buechler C, et al. Fatty acids as metabolic mediators in innate immunity. Eur J Clin Invest. 2009;39(10):924-33.
15. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 2008;8(12):923-34.
16. Youssef-Elabd EM, McGee KC, Tripathi G, Aldaghri N, Abdalla MS, Sharada HM, et al. Acute and chronic saturated fatty acid treatment as a key instigator of the TLR-mediated inflammatory response in human adipose tissue, in vitro. J Nutr Biochem. 2012;23(1):39-50.
17. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8(11):1211-7.
18. Lee HY, Oh E, Kim SD, Seo JK, Bae YS. Oxidized low-density lipoprotein-induced foam cell formation is mediated by formyl peptide receptor 2. Biochem Biophys Res Commun. 2014;443(3):1003-7.
19. Liu W, Yin Y, Zhou Z, He M, Dai Y. OxLDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation. Inflamm Res. 2014;63(1):33-43.
20. Geng H, Wang A, Rong G, Zhu B, Deng Y, Chen J, et al. The effects of ox-LDL in human atherosclerosis may be mediated in part via the toll-like receptor 4 pathway. Mol Cell Biochem. 2010;342(1-2):201-6.
21. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963): 296-300.
22. Iwata NG, Pham M, Rizzo NO, Cheng AM, Maloney E, Kim F. Trans fatty acids induce vascular inflammation and reduce vascular nitric oxide production in endothelial cells. PLoS One. 2011;6(12):e29600.
23. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515-81.
24. Frostegård J, Huang YH, Rönnelid J, Schäfer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17(5):963-8.
25. Nishi E, Kume N, Ueno Y, Ochi H, Moriwaki H, Kita T. Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ Res. 1998;83(5):508-15.
26. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arter Thromb Vasc Biol. 2000;20(9):2094-9.
27. Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34(4):788-802, e3.
28. Izar MC, Fonseca HA, Pinheiro LF, Monteiro CM, Póvoa RM, Monteiro AM, et al. Adaptive immunity is related to coronary artery disease severity after acute coronary syndrome in subjects with metabolic syndrome. Diab Vasc Dis Res. 2013;10(1): 32-9.
29. Matsuura E, Kobayashi K, Inoue K, Shoenfeld Y. Intravenous immunoglobulin and atherosclerosis. Clin Rev Allergy Immunol. 2005;29(3):311-9.
30. Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812-7.
31. Ruotsalainen E, Vauhkonen I, Salmenniemi U, Pihlajamäki J, Punnonen K, Kainulainen S, et al. Markers of endothelial dysfunction and low-grade inflammation are associated in the offspring of type 2 diabetic subjects. Atherosclerosis. 2008;197(1):271-7.
32. Imai Y, Dobrian AD, Weaver JR, Butcher MJ, Cole BK, Galkina EV, et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes Obes Metab. 2013;15 Suppl 3:117-29.
33. Maedler K, Dharmadhikari G, Schumann DM, Størling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol. 2011;203:257-78.
34. González-Chávez A, Elizondo-Argueta S, Gutiérrez-Reyes G, León-Pedroza JI. Implicaciones fisiopatológicas entre inflamación crónica y el desarrollo de diabetes y obesidad. Cir Cir. 2011;79(2):209-16.
35. Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012;35(8):1654-62.
36. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091): 87-91.
37. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
38. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945-51.
39. Dimitriadis K, Tsioufis K, Poulakis M, Lioni L, Flessas D, Kintis K, et al. Soluble receptor for advanced glycation end products levels are associated with asymmetric dimethylarginine and low-grade inflammation in essential hypertension. J Am Coll Cardiol. 2011;57(14s1). E1560-E1560.
40. De Groot AA, van Zwieten PA, Peters SLM. Involvement of reactive oxygen species in angiotensin II-induced vasoconstriction. J Cardiovasc Pharmacol. 2004;43(1):154-9.
41. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182-9.
42. Shimizu M, Ishikawa J, Yano Y, Hoshide S, Shimada K, Kario K. The relationship between the morning blood pressure surge and low-grade inflammation on silent cerebral infarct and clinical stroke events. Atherosclerosis. 2011;219(1):316-21.
43. Marfella R, Siniscalchi M, Portoghese M, Di Filippo C, Ferraraccio F, Schiattarella C, et al. Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque: role of ubiquitin-proteasome activity. Hypertension. 2007;49(4): 784-91.
44. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19(5):464-74.
45. Fragasso G, Spoladore R, Maranta F, Corti A, Lattuada G, Colombo B, et al. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure. J Cardiovasc Med (Hagerstown). 2013;14(1):49-56.